Principia Biopharma Inc.

Roivant Sciences Gmbh

Karos Pharmaceuticals, Inc.

Roche Palo Alto LLC

Altavant Sciences Gmbh

Kanos Pharmaceuticals, Inc.

Principia Biopharmac, Inc.

University of California

F. Hoffmann-la Roche Ag

Kenneth Albert Brameld

Eric Brian Sjogren

David Michael Goldstein

Erik J Verner

Daniel R Goldberg

Stéphane De Lombaert

Timothy D Owens

Andrew Scribner

Yan Lou

Jim W Li

Javier De Vicente Fidalgo

Francisco Xavier Talamas

Elbert Chin

Ryan Craig Schoenfeld

Stephane De Lombaert

David Scott Carter

Tim Owens

John William Taunton

Shyam Krishnan

Jesse McFarland

Jonathan Choy

Jesse Mcfarland

Timothy Duncan Owens

Jim Li

Tim A Owens

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Immunoproteasome inhibitors

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Quinolone derivatives as fibroblast growth factor receptor inhibitors

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

Spirocyclic compounds as tryptophan hydroxylase inhibitors

Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

LMP7 inhibitors

Quinolone derivatives as FGFR inhibitors

Growing community of inventors

Menlo Park, CA, United States of America

Kenneth Albert Brameld